SciSparc To Conduct Clinical Trial For Dronabinol-Based Drug To Treat Tourette Syndrome In Germany
Portfolio Pulse from Vuk Zdinjak
SciSparc Ltd. (NASDAQ:SPRC) has received approval from the Federal Institute for Drugs and Medical Devices in Germany for its phase IIb clinical trial of SCI-110, a drug for treating adults with Tourette syndrome. The trial will be conducted at three global centers of excellence, including the Yale Child Study Center, the Hannover Medical School, and the Tel Aviv Sourasky Medical Center. The company has secured the necessary approvals from all three clinical sites and the Israeli Ministry of Health.
July 03, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc's approval for the phase IIb clinical trial of SCI-110 could potentially boost the company's stock as it indicates progress in the company's drug development pipeline.
The approval for the phase IIb clinical trial of SCI-110 is a significant milestone for SciSparc. It indicates progress in the company's drug development pipeline, which could potentially attract investors and boost the company's stock. However, the actual impact will depend on the results of the trial and the market's perception of its potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100